Switch from Biktarvy to long-acting cabotegravir + rilpivirine every 2 months in virologically suppressed adults with HIV-1

Phase 3, randomised, open-label trial of cabotegravir, rilpivirine and bictegravir + emtricitabine + tenofovir alafenamide in Human immunodeficiency virus infection type 1 (2 arms), sponsored by ViiV Healthcare. Primary endpoint: Proportion of participants with plasma HIV-1 RNA at least 50 copies/mL at Month 12/Month 11 by FDA Snapshot. Started Aug 2020; status: completed.